Deltex Medical, the makers of a device which monitors blood flow during and after operations, says it is beginning to benefit from an official recommendation by the National Institute for Health and Clinical Excellence (NICE).In March last year NICE recommended that the CardioQ-ODM system be considered for use in all patients undergoing major and high risk surgery in the NHS. Since December Deltex has seen a 40% increase in sales of its surgical probes compared to the prior year.The firm still awaits the adoption of ODM as one of six "high impact" technologies to be implemented in the NHS but is pinning its hopes on a report to be published this Summer which may give the official stamp of approval.By 11:30 the stock had risen 2.7%.BS